drugset / Trial / NCT04311034
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of RC48-ADC for injection in subjects with advanced non-small cell lung cancer with HER2 overexpression or HER2 mutation.
Timeline
- Start
- 2018-09-26
- Primary completion
- 2021-12-21
- Completion
- 2022-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Other / unclassified | 2 mg/kg | — |